Yes, I am referring to response rate and also OS/PFS.
My man, I think you are only saying that because of what management have told you. There are multiple approved therapies for cholangiocarcinoma - chemo, targeted, immunotherapy, radiation, combinations. Roughly 8,000 patients each year leaves a very, very small slice of the pie even if it demonstrates some efficacy. Plenty of resources out there that confirm this. Also, clinicaltrials website show there are multiple phase 2 and 3 clinical trials currently recruiting for cholangiocarcinoma.
If the potential patient population is very low and there are already many options and potentials, the clinical risk is too high for the reward in my opinion.
All you have to do is look at CG0070 to see how difficult it is to go against the standard of care.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)